                                                    Concept  PeriodEnd                                                                                                                                                                                                                                             Dims        Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                  8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                  8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                                                                                  7.999000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.135500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.153900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.103600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 6.473000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 6.513000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 5.899000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.782800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.805200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.693500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.143000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.417000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                       srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 4.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 7.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.605000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.839000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.343000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.124000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.166000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.073000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.017000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.190000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.197000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.184000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 6.720000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 6.966000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 6.388000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.641000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.892000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.335000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.036100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.085800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 9.723000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.443000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.844000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.227000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 9.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 8.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.670000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 2.668000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 1.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.354000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.500000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.680000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.042000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.918000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.769000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.396000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 4.418000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 5.449000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.117000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.059000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                             srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                             srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.117000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                             srt:ProductOrServiceAxis:jnj:COVID19Member; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.179000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.241000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 9.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.272000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.150000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.008000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.446000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.494000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 4.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 4.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 4.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.712000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.854000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.943000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                   srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01          srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 2.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 3.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.398000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.065000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.570000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.718000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.323000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 7.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 7.140000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 6.893000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 5.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 5.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 6.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 7.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 6.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.125000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.897000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.714000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.097000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.218000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.426000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.222000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.140000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 9.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 5.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 4.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.077000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 6.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 9.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.204000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.358000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.175000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.553000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.734000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.085400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 8.462000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.930000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.926000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.199000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.052000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.078100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.766100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.598300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 8.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.588000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.277000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                            srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.210000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.467000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.767000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.167000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.744000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 7.977000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.282000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.065000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.717000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.322000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.999000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.387000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.881000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.020000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.051000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.390000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.018000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.214000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.394000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.264000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.784000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                              srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 3.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                              srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                              srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 7.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 8.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.696000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 8.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.770000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 2.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 4.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 3.143000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.697000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.346000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.140000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.117000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.071000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 4.282000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 3.815000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 3.417000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.520000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.292000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.132000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 6.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 6.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 6.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.184000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.973000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.783000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.511000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.326000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.104000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 3.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.817000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.582000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.322000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 7.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01             srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01    srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 3.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.866000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.906000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 3.042000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 6.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 7.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 3.562000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 3.671000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 3.887000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.365000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.473000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.365000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 2.473000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 5.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                          srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 5.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 6.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 7.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 1.189000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 1.414000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.397000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.116900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.860400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.299400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.359000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.395900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.696400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.475900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.256300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 4.513000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.633000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.169000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.194000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.717000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.131000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 7.707000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 6.350000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 4.300000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.738000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.458000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.036000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.529000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.230000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.901000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 5.267000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 4.688000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.937000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                  srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.213000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                  srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.066000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                  srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                         srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                         srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.496000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                     srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                               srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 5.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.689000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.525000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.321000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 3.470000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 3.417000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 3.267000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 9.158000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 8.942000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 8.587000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.057000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 9.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                       srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 9.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.638000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.560000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.514000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 9.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 8.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                      srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 8.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 6.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 5.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.545000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.456000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.359000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                     srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.013000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                     srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.949000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                     srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.882000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.036000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.030000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 9.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 3.049000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.979000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.871000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.696000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.684000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                           srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.645000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.230000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.263000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 1.198000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.926000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.947000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.843000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.003000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.031000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 3.897000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 5.842000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 6.006000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 5.793000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 9.845000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 1.003700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 9.690000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 1.838000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 1.833000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                        srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 1.784000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.650000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.837000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                               srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.785000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.488000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.671000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.569000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.198000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.113000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 3.192000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 3.168000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 3.008000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 5.358000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 5.366000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 5.121000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.128000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.086000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.990000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 3.018000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.986000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.859000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 5.146000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 5.072000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 4.849000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.684000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.626000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                               srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.522000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.049000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.022000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 3.733000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 3.702000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 3.543000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 4.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 4.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                         srt:StatementGeographicalAxis:country:US; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 4.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 9.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 9.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 8.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.413000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.370000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.633200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.527500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.337700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.552500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.512500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.405000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.185700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.040000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.742700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 5.030200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 4.644400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 4.198100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.851900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.871500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.800900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                  8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                  8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                                                                                  7.999000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.696400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.185700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.475900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.040000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.256300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.742700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                             srt:StatementGeographicalAxis:country:US; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 5.030200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                             srt:StatementGeographicalAxis:country:US; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 4.644400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                             srt:StatementGeographicalAxis:country:US; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 4.198100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                       srt:StatementGeographicalAxis:srt:EuropeMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 2.021200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                       srt:StatementGeographicalAxis:srt:EuropeMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 2.041000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                       srt:StatementGeographicalAxis:srt:EuropeMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 2.066400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                 srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 4.714000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                 srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 4.549000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                 srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 4.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                            srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 1.359300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                            srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 1.375600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                            srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember; srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 1.323700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember 7.999000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                  8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                  8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-01-01                                                                                                                                                                                                                                                  7.999000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  2.374300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  2.244700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  4.563600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  4.383000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.385000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.636000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.398000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.019000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.928000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.455000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.592000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.885000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 6.312000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 5.090000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 1.199000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember 9.904000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.017000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.641000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.846000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.105000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.521000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.237000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.930000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.465000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.539000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.878000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.776000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.570000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.679000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.425000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.043000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.444000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.554000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.505000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.978000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.701000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.431000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.489000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.744000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.999000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.538000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 3.993000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 4.722000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 7.700000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember 8.969000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.349000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.091000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.078000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.855000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.059000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.251000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.030000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.219000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.085000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.653000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.885000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.278000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.336000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.395000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.098000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.186000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.142000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.714000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.377000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.102000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.345000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.156000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.353000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.428000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 2.051000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 1.782000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.698000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember 3.585000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                         srt:ProductOrServiceAxis:jnj:CAPLYTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                         srt:ProductOrServiceAxis:jnj:CAPLYTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                   srt:ProductOrServiceAxis:jnj:CAPLYTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                   srt:ProductOrServiceAxis:jnj:CAPLYTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.357000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.549000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.054000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.895000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.110000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.543000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.509000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.113000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 1.039000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.138000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember 2.088000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.104000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.072000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.128000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 8.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 9.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.605000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember 1.786000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 4.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 7.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.631000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.348000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 9.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 8.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 1.943000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember 1.721000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.105000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.105000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 3.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 9.161000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 8.510000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.725300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.612200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 6.041000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 5.980000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.182200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.193000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.520200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.449000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.907500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.805200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.364000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.119000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.625000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.144000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.790000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.534000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 2.313000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 1.873000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 4.416000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember 3.679000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.425000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.397000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.366000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.270000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember 1.468000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember 1.323000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember 2.791000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember 2.667000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember 4.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember 3.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember 8.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember 7.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember 2.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember 5.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember 1.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember 9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember 2.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember 1.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.420000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.422000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.804000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.870000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.742000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.782000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.305000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 2.312000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 4.546000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember 4.652000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.003000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.002000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.540000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.524000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.398000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.495000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.043000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.045000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.982000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.512000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.493000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.906000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.922000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.555000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 2.488000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.951000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember 4.904000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 6.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.303000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.316000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.164000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.141000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.237000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.228000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.111000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.070000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.603000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.606000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.391000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.346000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.714000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.676000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.123000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.070000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.526000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.473000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.369000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 1.285000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.648000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember 2.543000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.003000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 9.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.884000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.828000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 2.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 5.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.383000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.059000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.596000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.067000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 4.158000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 3.898000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.965000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.711000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.541000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.957000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.656100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.577800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 1.354400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 1.256900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 2.584900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 2.418900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.019900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 9.878000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.978700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.964100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  2.374300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  2.244700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  4.563600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  4.383000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.520200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 8.541000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 1.449000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 7.957000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.907500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.656100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember 2.805200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember 1.577800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 1.354400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 1.256900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 2.584900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US 2.418900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember 5.387000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember 5.214000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember 1.049700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember 1.037700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember 1.206000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember 1.212000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember 2.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember 2.406000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember 3.606000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember 3.452000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember 6.917000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember 6.858000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  2.374300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  2.244700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                                                                                                  4.563600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                                                                                                  4.383000e+10